title: Male breast cancer: clinical features and multimodal treatment in a retrospective survey analysis at Italian centers.
abstract: OBJECTIVE
  We report a collection of data about early breast cancer in male patients from 13 Italian institutions.
  
  
  METHODS
  We obtained data from patient charts and performed statistical analysis. The primary end points were overall survival and disease-free survival.
  
  
  RESULTS
  A total of 205 men with invasive breast cancer was identified, with a median age of 66 years. Pathological characteristics were heterogeneous for T stage, N stage and HER2 status. Histological subtype was predominantly ductal infiltrating carcinoma. Most of them were hormone receptor positive. Mastectomy was the most common strategy. Postsurgical treatment was not standardized. Patients with large tumors were more likely to be treated with chemotherapy. Disease recurrence was associated with an ER+ and PR+ status.
  
  
  CONCLUSIONS
  We identified a correlation between relapse and hormone receptor expression, as is the case in female breast cancer.
authors.forename: Nicla
authors.initials: N
authors.lastname: La Verde
authors.forename: Elena
authors.initials: E
authors.lastname: Collovà
authors.forename: Sara
authors.initials: S
authors.lastname: Lonardi
authors.forename: Daniele
authors.initials: D
authors.lastname: Generali
authors.forename: Anna
authors.initials: A
authors.lastname: Moretti
authors.forename: Francesco
authors.initials: F
authors.lastname: Atzori
authors.forename: Marina
authors.initials: M
authors.lastname: Cazzaniga
authors.forename: Chiara
authors.initials: C
authors.lastname: Saggia
authors.forename: Luca
authors.initials: L
authors.lastname: Tondulli
authors.forename: Ilaria
authors.initials: I
authors.lastname: Marcon
authors.forename: Anna Lisa
authors.initials: AL
authors.lastname: Gentile
authors.forename: Rosalba
authors.initials: R
authors.lastname: Rossello
authors.forename: Olga
authors.initials: O
authors.lastname: Martelli
authors.forename: Stefania
authors.initials: S
authors.lastname: Aglione
authors.forename: Gabriella
authors.initials: G
authors.lastname: Farina
authors.forename: Michela
authors.initials: M
authors.lastname: Cinquini
authors.forename: Marina
authors.initials: M
authors.lastname: Garassino
mesh_terms: D000328:Adult; D000368:Aged; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000032:analysis*; D018567:Breast Neoplasms, Male / Q000737:chemistry / Q000175:diagnosis / Q000401:mortality* / Q000473:pathology / Q000628:therapy*; D017024:Chemotherapy, Adjuvant; D018572:Disease-Free Survival; D006801:Humans; D007558:Italy / Q000453:epidemiology; D053208:Kaplan-Meier Estimate; D008297:Male; D008408:Mastectomy; D008499:Medical Records; D008875:Middle Aged; D009367:Neoplasm Staging; D018714:Radiotherapy, Adjuvant; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis; D011960:Receptors, Estrogen / Q000032:analysis; D011980:Receptors, Progesterone / Q000032:analysis; D012008:Recurrence; D012189:Retrospective Studies; D018570:Risk Assessment; D012307:Risk Factors; D016896:Treatment Outcome; D064726:Triple Negative Breast Neoplasms / Q000175:diagnosis / Q000401:mortality
chemical_list: D018931:Antineoplastic Agents, Hormonal; D014408:Biomarkers, Tumor; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; C508053:ERBB2 protein, human